Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in North America

American Journal of Epidemiology

Volumn 174, Issue 6, 2011, Pages 727-735

  Abraham, Alison G ^a   Lau, Bryan ^a   Deeks, Steven ^a   Moore, Richard D ^a   Zhang, Jinbing ^a   Eron, Joseph ^a   Harrigan, Richard ^a   Gill, M John ^a   Kitahata, Mari ^a   Klein, Marina ^a   Napravnik, Sonia ^a   Rachlis, Anita ^a   Rodriguez, Benigno ^a   Rourke, Sean ^a   Benson, Constance ^a   Bosch, Ron ^a   Collier, Ann ^a   Gebo, Kelly ^a   Goedert, James ^a   Hogg, Robert ^a   Horberg, Michael ^a   Jacobson, Lisa ^a   Justice, Amy ^a   Kirk, Greg ^a   Martin, Jeff ^a   Mckaig, Rosemary ^a   Silverberg, Michael ^a   Sterling, Timothy ^a   Thorne, Jennifer ^a   Willig, James ^a   Gange, Stephen J ^a   more..

^a NONE

Author keywords

antiretroviral therapy, highly active; drug resistance; genotype; HIV

Indexed keywords

ABACAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALGORITHM; ANTIMICROBIAL ACTIVITY; BIOACCUMULATION; COHORT ANALYSIS; DATA SET; DISEASE PREVALENCE; DRUG RESISTANCE; ESTIMATION METHOD; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; COMBINATION CHEMOTHERAPY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PREVALENCE; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; NORTH AMERICA; PREVALENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RNA, VIRAL; TIME FACTORS;

NORTH AMERICA;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 80052653662     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr141     Document Type: Article

References (36)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-860. (Pubitemid 28135961)
2. Deeks SG, Barbour JD, Martin JN, et al. Sustained CD4p T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 2000;181(3):946-953. (Pubitemid 30194478)
3. Lucas GM. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J Antimicrob Chemother. 2005;55(4):413-416. (Pubitemid 40542576)
4. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet. 2003;362(9400):2002-2011. (Pubitemid 37548427)
5. Napravnik S, Keys JR, Quinlivan EB, et al. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1- infected patients. AIDS. 2007;21(7):825-834. (Pubitemid 46573154)
6. Office of National AIDS Policy. 2010 National HIV/AIDS Strategy. Washington, DC: Office of National AIDS Policy; 2010. (http://www.whitehouse. gov/administration/eop/onap/ nhas/). (Accessed March 1, 2011).
7. Siliciano JD, Siliciano RF. A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother. 2004;54(1):6-9. (Pubitemid 39028960)
8. Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol. 1995;142(12):1255-1264. (Pubitemid 26006424)
9. Vach W, Blettner M. Biased estimation of the odds ratio in case-control studies due to the use of ad hoc methods of correcting for missing values for confounding variables. Am J Epidemiol. 1991;134(8):895-907.
10. Rubin DB. Multiple imputation after 18p years. J Am Stat Assoc. 1996;91(434):473-489.
11. Little RJA, Rubin DB. Statistical Analysis With Missing Data. New York, NY: John Wiley &Sons, Inc; 2002.
12. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1- Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2009. (http://www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf). (Accessed May 14, 2010).
13. Gange SJ, Kitahata MM, Saag MS, et al. Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol. 2007;36(2):294-301. (Pubitemid 47064328)
14. Rhee SY, Gonzales MJ, Kantor R, et al. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003;31(1):298-303 (Pubitemid 36150389)
15. Bannister WP, Kirk O, Gatell JM, et al. Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. J Acquir Immune Defic Syndr. 2006;42(2):229-237. (Pubitemid 43884719)
16. Lampe FC, Gatell JM, Staszewski S, et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med. 2006;166(5):521-528.
17. Lohse N, Obel N, Kronborg G, et al. Declining risk of tripleclass antiretroviral drug failure in Danish HIV-infected individuals. AIDS. 2005;19(8):815-822. (Pubitemid 40834752)
18. Deeks SG, Gange SJ, Kitahata MM, et al. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis. 2009;49(10):1582-1590.
19. de Mendoza C, Garrido C, Corral A, et al. Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. AIDS Res Hum Retroviruses. 2007;23(7): 879-885. (Pubitemid 47267494)
20. Di Giambenedetto S, Bracciale L, Colafigli M, et al. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. Antivir Ther. 2007;12(5):835-839. (Pubitemid 47235499)
21. Vercauteren J, Deforche K, Theys K, et al. The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology. 2008;5(1):12. (doi:10.1186/1742-4690-5- 12).
22. Hirsch MS, Günthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008;47(2):266-285. (Pubitemid 351920631)
23. Bangsberg DR, Acosta EP, Gupta R, et al. Adherenceresistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20(2):223-231.
24. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007;4(2):65-72. (Pubitemid 46806622)
25. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J InfectDis. 2005;191(3): 339-347. (Pubitemid 40139758)
26. von Wyl V, Yerly S, Böni J, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med. 2007;167(16):1782-1790. (Pubitemid 47403067)
27. Rubin DB, Stern HS, Vehovar V. Handling don't know survey responses: the case of the Slovenian plebiscite. J Am Stat Assoc. 1995;90(431):822-828.
28. Hermankova M, Ray SC, Ruff C, et al. HIV-1 drug resistance profiles in children and adults with viral load of (Pubitemid 32640851)
29. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347(6):385-394. (Pubitemid 34851830)
30. Lima VD, Harrigan PR, Sénécal M, et al. Epidemiology of antiretroviral multiclass resistance. Am J Epidemiol. 2010; 172(4):460-468.
31. Grover D, Copas A, Green H, et al. What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? J Antimicrob Chemother. 2008;61(3):705-713. (Pubitemid 351321150)
32. Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med. 2006;3(9):e356. (doi: 10.1371/journal.pmed.0030356).
33. Lucas GM, Gallant JE, Moore RD. Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing. AIDS. 2004;18(11):1539-1548. (Pubitemid 39037478)
34. Mocroft A, Ledergerber B, Viard JP, et al. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis. 2004;190(11):1947-1956. (Pubitemid 39564700)
35. Raffanti SP, Fusco JS, Sherrill BH, et al. Effect of persistent moderate viremia on disease progression during HIV therapy. J Acquir Immune Defic Syndr. 2004;37(1):1147-1154. (Pubitemid 39166649)
36. Recsky MA, Brumme ZL, Chan KJ, et al. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy. J Infect Dis. 2004;190(2):285-292. (Pubitemid 38951968)